A new study identifies DOPA decarboxylase in spinal fluid as a precise biomarker for Parkinsons and Lewy body dementia. This discovery offers a reliable way to distinguish these diseases from Alzheimer's, reducing the risk of harmful misdiagnosis.
Precision Biomarker for Parkinsons and Lewy Body Dementia Found
Neuroscience News - 24 Mar 2026 16:29
A new study identifies DOPA decarboxylase in spinal fluid as a precise biomarker for Parkinsons and Lewy body dementia. This discovery offers a reliable way to distinguish these diseases from Alzheimer's, reducing the risk of harmful misdiagnosis.
Share this Article
Recommended